IGFBP2 and Alzheimer disease: Therefore, the development of a wider and more AD-oriented kit, which would allow the quantification of other highly reproducible CBs not included in the current one and, thus, not measured now (such as, for example, pancreatic prohormone, serum amyloid P component, interleukin-3, Insulin-like growth factor-binding protein 2, etc.)should be done in further studies and could significantly improve the results.